Responding to the publication of the updated WHO Model List of Essential Medicines (EML), IFPMA Director General, Dr. David Reddy said:  

“The inclusion of innovative medicines on the updated EML highlights how scientific advances are transforming how we prevent, treat and cure disease, and reinforces the importance of ensuring patients everywhere can benefit from them.  

“Pharmaceutical companies work with governments and healthcare systems around the world to drive access to medicines and vaccines, including through tiered pricing, voluntary licensing and value-based healthcare models.

“Alongside this, healthcare systems need to be strengthened with the right infrastructure, diagnostics and trained professionals in place, alongside effective regulatory pathways and sustainable procurement, to help ensure these innovations can achieve greatest impact for patients. 

“We welcome the opportunity to contribute our expertise to the EML process, to help ensure that   decisions are informed by the most current and robust evidence, while maintaining the policies and IP framework that sustains the innovation our companies deliver for patients.”